ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 0100

Rheumatoid Arthritis Remains Associated with Lower Humoral but not Cellular Immune Response Beyond Primary COVID mRNA Vaccine Series in US Veterans

Mahathi Chitti1, Sara Behrens2, Lenche Kostadinova2, Holly Dudley3, Megan O'mara1, Eric Hall4, Lindsay Allamon4, Laura Silversteyn4, Shahdi Malakooti5, Christopher King6, Jurgen Bosh6, David Canaday6, David Zidar6, Maya Mattar7, Brigid Wilson4, Carey Shive6 and Donald Anthony8

Affiliations: 1Case Western Reserve University, Cleveland, 2Cleveland VA Medical Center, Cleveland, 3Case Western Reserve University, Cleveland Heights, OH, 4Cleveland VA Medical Center, Cleveland, OH, 5MetroHealth at Case Western Reserve University, Cleveland, OH, 6Case Western Reserve University, Cleveland, OH, 7Louis Stokes VA medical Center, Mayfield Village, OH, 8Case, VA, Metro, Chardon, OH

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: COVID-19, Disease-Modifying Antirheumatic Drugs (Dmards), immunology, rheumatoid arthritis

Session Information

Date: Sunday, November 8, 2026

Title: (0093-0103) Rheumatoid Arthritis - Etiology & Pathogenesis Poster A

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Persons with rheumatoid arthritis (RA) are known to have lower antibody responses to primary series COVID-19 vaccine, and immunosuppressive medications used to treat RA are thought to be at least in part responsible. At the same time, additional doses of COVID vaccine have been thought to ameliorate this gap. We have previously observed lower antibody and T cell response to the primary 2 dose COVID mRNA vaccine series in persons with RA, and this was associated with age, RA disease status and medications used to treat RA. Here we sought to understand whether additional vaccine doses could close the gap in COVID vaccine induced immunity comparing RA patients and controls.

Methods: We evaluated serum samples taken in a cross sectional cohort of RA patients (n=99) and non-autoimmune disease controls (n=131), for anti-spike IgG levels to Wuhan, BA.1, BA.5, XBB1.5, JN.1, and KP.2 spike protein, and analyzed results with regard to time since last vaccine dose, number of vaccine doses, evidence of prior COVID exposure (presence of nucleocapsid protein (NCP) antibody), age, race, sex and RA treatment. Additionally, we assessed peripheral blood mononuclear cells (PBMC) for spike-specific IFN-γ and IL-2 production by ELISPOT assay and compared between RA and control groups.

Results: In models adjusting for number of doses of vaccine, time since last vaccine, NCP antibody status, sex and age, RA participants had lower Wuhan, BA.1, BA.5, XBB.1.5, JN.1, and KP.2 spike protein spike-specific IgG levels than controls. Wuhan antibody levels were lowest in RA participants taking conventional disease modifying antirheumatic drugs (DMARDS), abatacept or rituximab, and, antibody levels were higher in participants that had 3+ doses of vaccine compared to those with 2 doses. Spike specific PBMC IFN-γ and IL-2 producing immunity was similar comparing RA and control groups.

Conclusion: These data indicate lower COVID-19 mRNA vaccine-induced antibody levels in persons with RA compared to individuals without RA persist after over 2 doses of vaccine, after adjusting for number of vaccine doses, recent infection, and time since vaccine. This diminished response is likely in part attributable to immune modulatory therapies used to treat RA. At the same time, cellular immune response to COVID-19 vaccines is comparable between RA and control groups.


Disclosures: M. Chitti: None; S. Behrens: None; L. Kostadinova: None; H. Dudley: None; M. O'mara: None; E. Hall: None; L. Allamon: None; L. Silversteyn: None; S. Malakooti: None; C. King: None; J. Bosh: None; D. Canaday: None; D. Zidar: None; M. Mattar: None; B. Wilson: None; C. Shive: None; D. Anthony: None.

To cite this abstract in AMA style:

Chitti M, Behrens S, Kostadinova L, Dudley H, O'mara M, Hall E, Allamon L, Silversteyn L, Malakooti S, King C, Bosh J, Canaday D, Zidar D, Mattar M, Wilson B, Shive C, Anthony D. Rheumatoid Arthritis Remains Associated with Lower Humoral but not Cellular Immune Response Beyond Primary COVID mRNA Vaccine Series in US Veterans [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-remains-associated-with-lower-humoral-but-not-cellular-immune-response-beyond-primary-covid-mrna-vaccine-series-in-us-veterans/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-remains-associated-with-lower-humoral-but-not-cellular-immune-response-beyond-primary-covid-mrna-vaccine-series-in-us-veterans/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology